Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
AL2846 in NSCLC with bone metastases
CTR20200413Phase 2Terminated
- Sponsor
- Adcent Pharmaceutical
- Start
- Mar 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
A Phase 2 trial of vilzemetkib in non-small cell lung cancer (NSCLC), bone metastases, sponsored by Adcent Pharmaceutical. Started Mar 2020; status: terminated.
02
Drugs
vilzemetkib
03
Conditions
non-small cell lung cancer (NSCLC)bone metastases
Beyond the preview
Go deeper on CTR20200413.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on CTR20200413.